GFPC
PCVX icon

Global Financial Private Client’s Vaxcyte PCVX Stock Holding History

Global Financial Private Client’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1
Closed -$82 – 1693
2024
Q4 		$82 Buy
+1
New +$99 ﹤0.01% 1518

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Global Financial Private Client's PCVX Position: Q1 2025 in Review

Global Financial Private Client sold out of Vaxcyte (PCVX) in Q1 2025, closing a stake of 1 share — an estimated $82 sold.

Global Financial Private Client first reported a position in PCVX in Q4 2024 and held it in 1 quarter. The position peaked at $82 in Q4 2024. 315 funds tracked by Wall St. Rank hold PCVX as of Q1 2025.

  • Global Financial Private Client reported no remaining Vaxcyte position as of Q1 2025 after selling out during the quarter.
  • Global Financial Private Client sold 1 Vaxcyte share in Q1 2025, an estimated $82.
  • Global Financial Private Client first reported a position in Vaxcyte in Q4 2024 and held it in 1 quarter.
  • Global Financial Private Client's Vaxcyte position peaked at $82 in Q4 2024.
  • 315 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2025.

Based on Global Financial Private Client's 13F filing for Q1 2025, filed 8 Apr 2025.